Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Sounds Like

<< Previous

Bullboard Posts

Next >>

Comment by steadytradeson Sep 11, 2020 1:11pm

223 Views

Post# 31543320

RE:Sounds Like

Im sure he has contacted managment since the last stock issue to assure him and his family of the holdings they have with Antibe.

If he was not happy with ATE he did not have to suggest to the caller that he would rather own ATE vs the stock the caller called about.

I think its good that he had a positive comment on ATE in light of no news from ATE.

<< Previous

Bullboard Posts

Next >>

This battery metals stock is on a path to the global stage